Showing 3391-3400 of 10618 results for "".
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
https://reachmd.com/programs/conversations-in-cv-risk-assessment/rethinking-cardiovascular-risk-uncovering-the-blind-spots/36242/Tune in to hear Dr. Jennifer Caudle and Dr. Javed Butler—Professor of Medicine at the University of Mississippi Medical Center and Senior VP at Baylor Scott and White Health in Dallas, Texas—discuss the role of urine albumin-to-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR)Elevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
https://reachmd.com/programs/conversations-in-cv-risk-assessment/elevating-cv-risk-assessment-why-uacr-deserves-a-seat-at-the-table/36245/Could kidney-related markers like urine albumin-to-creatinine ratio (uACR) reshape how clinicians approach cardiovascular risk discussions? To explore this question, Dr. Brian McDonough sits down with Dr. Javier Morales, Associate Professor of Medicine at the Donald and Barbara Zucker School of MediPrimary Care and Cardiology: Shared Responsibility in Albuminuria Detection
https://reachmd.com/programs/conversations-in-cv-risk-assessment/primary-care-and-cardiology-shared-responsibility-in-albuminuria-detection/36253/What does coordinated albuminuria screening look like in practice? Hear Dr. Jennifer Caudle and Drs. Javed Butler and Martha Gulati discuss practical strategies for assessment across primary, cardiology, and nephrology settings. Dr. Butler is Professor of Medicine at the University of Mississippi MeExpanding Treatment Options in PNH: Expert Approaches to Personalized Care
https://reachmd.com/programs/medical-industry-feature/pnh-expert-approaches-personalized-care/35651/Managing patients with paroxysmal nocturnal hemoglobinuria (PNH) is never a “one-size-fits-all” approach. With the emergence of a therapy like FABHALTA® (iptacopan), which delivers comprehensive control of intravascular and extravascular hemolysis, we have an option to offer to eligible adult patienPharmacology of Emerging Selective Sodium Channel Antagonists for the Treatment of Epilepsy
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/pharmacology-of-emerging-selective-sodium-channel-antagonists-for-the-treatment-of-epilepsy/39904/The development of isoform-selective sodium channel inhibitors that spare GABAergic interneuron function is in its early stages but holds promise as an exciting area of research.Addressing Unmet Needs in Metastatic Uveal Melanoma
https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bNew Pathways in the Treatment of DMD
https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, musclRethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
https://reachmd.com/programs/cme/secondary-stroke-prevention-emerging-role-factor-xi-inhibition/50969/Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break do10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
https://reachmd.com/programs/project-oncology/portec-3-chemoradiotherapy-high-risk-endometrial-cancer/39928/Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
https://reachmd.com/programs/neurofrontiers/sabirnetug-early-alzheimers/40000/